期刊文献+

我院他汀类药物治疗费用分析 被引量:7

Analysis of Treatment Costs of the Statins in Our Hospital
原文传递
导出
摘要 目的:评价不同他汀类药物降低低密度脂蛋白胆固醇(LDL-C)相同水平时的费用。方法:对该院6种他汀类药物(普伐他汀10-40 mg/d;辛伐他汀10-80 mg/d;氟伐他汀40-80 mg/d;阿托伐他汀10-80 mg/d;瑞舒伐他汀5-20 mg/d;匹伐他汀1-4 mg/d)进行最小成本比较。结果:降低LDL-C水平〈35%时,辛伐他汀的费用最低;而降低LDL-C水平〉35%时,瑞舒伐他汀的费用最低。合理选择他汀类药物最多可为每位患者每年节约5 617.35元。同种药物原研药与仿制药之间费用差异不大(普伐他汀除外)。结论:应根据具体情况选择药物,既可以实现降脂目标,又可以节约医疗成本,实现资源的最大利用。 OBJECTIVE:To evaluate the treatment cost of different kinds of statins in the same reduction of LDL-C.METHODS:The minimum costs of 6 kinds of statins were compared in our hospital,i.e.pravastatin 10-40 mg/d,simvastatin 10-80 mg/d,fluvastatin 40-80 mg/d,atorvastatin 10-80 mg/d,rosuvastatin 5-20 mg/d,pitavastatin 1-4 mg/d.RESULTS:When the percentage of LDL-C was lowered by 35%,simvastatin was the cheapest treatment choice;while rosuvastatin became preferred when the percentage of LDL-C was lowered by35%.A maximum of 5617.35 yuan per patient per year could be saved when the preferred statin was used.The treatment costs of original drug and generic drugs were similar(except for pravastatin).CONCLUSIONS:The drugs should be selected according to the situation,so that a lot of medical cost and resources could be saved without reduction of efficacy.
出处 《中国药房》 CAS CSCD 2013年第34期3169-3172,共4页 China Pharmacy
关键词 他汀类药物 血脂异常 低密度脂蛋白胆固醇 费用分析 合理用药 Statin Dyslipidemia LDL-C Cost analysis Rational drug use
  • 相关文献

参考文献7

  • 1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5222
  • 2宦璐.仿制药迅猛他汀药概念望爆发(股)[EB/OL].(2011-12-23)[2013-07-04].http://company.cnstock.com/listed/top/201112/1758140.htm.
  • 3National Cholesterol Education Program. Executive summa- ry of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatmem of high blood cholesterol in adults: adult treatment panel Ⅲ [J]. JAM_A, 2001,285(19) : 2 486.
  • 4Baigent C, Keech A, Keamey PM, et al. Efficacy and safe- ty of cholesterol-lowering treatment, prospective meta- analysis of data from 90 056 participants in I4 randomised trials of statins[J]. Lancet, 2005 (9 493) : 1 267.
  • 5Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and me- ta-analysis[J]. BMJ, 2003 (7 404) : 1 423.
  • 6FDA Drug Safety Communication. New restrictions, con-traindications, and dose limitations for Zocor (simvas- tatin) to reduce the risk of muscle injury[EB/OL]. (2011-12-15) [2013-07-04].http ://www.fda.gov/drugs/ drugsafety/ucm256581.htm.
  • 7Leung A, Schaefer EW, Tempelhof MW, et al. Empha- sizing statin safety in the hospitalized patient: a review [J]. Am JMed,2012,125(9):845.

二级参考文献149

共引文献5221

同被引文献56

引证文献7

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部